Abgeschlossene Studien
| Studie | Studienleiter | Publikationen |
| Akute Hepatitis B | Prof. Dr. med. Hans L. Tillmann | |
| Akute Hepatitis C I | Prof. Dr. M. P. Manns | |
| Akute Hepatitis C II | Prof. Dr. M. P. Manns | Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany – Dintsios CM, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, Manns MP, Krauth C.: Eur J Gastroenterol Hepatol. 2009 Jun 22 Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection – Vogel M, Deterding K, Wiegand J, Grüner NH, Baumgarten A, Jung MC, Manns MP, Wedemeyer H, Rockstroh JK; German Hepatitis Group; Hep-Net: Clin Infect Dis. 2009 Jul 15;49(2):317-9 The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection – Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, Jung MC, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H.: Z Gastroenterol. 2009 Jun;47(6):531-40 Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis – Wiegand J, Cornberg M, Aslan N, Schlaphoff V, Sarrazin C, Kubitschke A, Buggisch P, Ciner A, Jaeckel E, Manns MP, Wedemeyer H.: Antivir Ther. 2007;12(3):303-16. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study – Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group: Hepatology. 2006 Feb;43(2):250-6. Long-term follow-up after successful interferon therapy of acute hepatitis – Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H.: Hepatology. 2004 Jul;40(1):98-107. |
| CIPPAD | Prof. Dr. T. Berg PD Dr. M. Schäfer |
Schäfer et al., AASLD 2008 |
| Genotyp 2/3 Studie | Prof. Dr. med. S. Zeuzem | Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.:Gastroenterology. 2005 Aug;129(2):522-7. |
| GIHALT (LTx) | Prof. Dr. med. Michael P. Manns | |
| GT 2-3 Heidelberg | Frau PD Dr. med. B. Kallinowski | |
| HBV/HCV Koinfektion | Prof. Dr. med. C. Trautwein, Prof. Dr. med. M.P. Manns |
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in patients with HBV/HCV co-infection - Andrej Potthoff, Heiner Wedemeyer, Wulf O. Böcher, Thomas Berg, Stefan Zeuzem, Joachim Arnold, Ulrich Spengler, Kurt Grüngreiff, Thomas Käser, Adam Kassai, Marcus Schuchmann, Alexandra Bergk, Nicole Forestier, Katja Deterding, Michael P. Manns, Christian Trautwein for the Hep-Net B/C Co-infection Study Group.. Journal of Hepatology 2008 , Volume 49 , Issue 5 , Pages 688 – 694. Late HBV relapse in patients co-infected with HBV and HCV after antiviral treatment with pegylated interferon-a2b (PEG-IFN-a2b) and ribavirin – Potthoff A, Berg T, Wedemeyer H for the HEP-NET B/C co-infection study group.. Scand J Gastroenterol. 2009;44(12):1487-90. |
| HCV Genotyp 1 | Dr. med. T. Berg, Prof. Dr. med. Hopf |
|
| HCV-Longterm-PEG | PD Dr. A. Erhardt, Prof. Dr. D. Häussinger |
|
| Hepatische Fibrose | Prof. Dr. med. S. Zeuzem | |
| HIDIT 1 | Prof. Dr. med. M.P. Manns, Prof. Dr. med. H. Wedemeyer |
Yurdaydin et al., AASLD 2006; Wedemeyer et al., EASL 2007 |
| PIMODI | Prof. Dr. med. R. Zachoval | |
| Prama | Prof. Dr. med. S. Zeuzem | Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection - von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S. Hepatology. 2008 Nov;48(5):1404-11. |
| Redd 2/3 | Prof. Dr. med. M.P. Manns, Prof. Dr. med. H. Wedemeyer |
Manns et al., EASL 2009 Manns et al., AASLD 2009 |
| TRELA Relapse | Dr. P. Buggisch | Buggisch et al., EASL 2009 |
